| Name | cog 133 |
|---|---|
| Synonyms |
COG 133 trifluoroacetate salt
apoE(13 N-acetyl-L-leucyl-L-ginyl-L-valyl-L-ginyl-L-leucyl-L-alanyl-L-seryl-L-histidyl-L-leucyl-L-ginyl-L-lysyl-L-leucyl-L-ginyl-L-lysyl-L-ginyl-L-leucyl-L-Leucinamide Ac-Leu-g-Val-g-Leu-Ala-Ser-His-Leu- g-Lys-Leu-g-Lys-g-Leu-Leu-NH2 apoE L-Leucinamide, N-acetyl-L-leucyl-L-ginyl-L-valyl-L-ginyl-L-leucyl-L-alanyl-L-seryl-L-histidyl-L-leucyl-L-ginyl-L-lysyl-L-leucyl-L-ginyl-L-lysyl-L-ginyl-L-leucyl COG 133 TFA salt Ac- VRLASHKKRLL-NH2 COG-133; COG133 |
| Description | COG 133 is a fragment of Apolipoprotein E (APOE) peptide. COG 133 competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 is also a nAChR antagonist with an IC50 of 445 nM[1][2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 445 nM (nAChR)[2] |
| References |
| Molecular Formula | C97H181N37O19 |
|---|---|
| Molecular Weight | 2169.71000 |
| Exact Mass | 2168.43000 |
| PSA | 948.24000 |
| LogP | 7.91900 |